Table 2 Toxicity profile of 30 evaluable patients.

From: Efficacy and safety of angiogenesis inhibitors plus immune checkpoint inhibitors in advanced soft tissue sarcoma: a real-world, single-center study

Toxicity

Any grade, n (%)

 ≥ Grade 3, n (%)

Hypertension

15 (50.0)

9 (27.3)

ECG T-wave abnormality

9 (30.0)

Hypothyroidism

8 (26.7)

2 (6.7)

Elevated alanine aminotransferase or aspartate aminotransferase

7 (23.3)

1 (3.3)

Elevated thyroid-stimulating hormone

7 (23.3)

Fatigue

5 (16.7)

Elevated γ-glutamyltransferase

4 (13.3)

Hyperbiliubinemia

4 (13.3)

Hand-foot syndrome

3 (10.0)

Hypertriglyceridemia

3 (10.0)

Hyperthyroidism

3 (10.0)

Elevated B-type natriuretic peptide

3 (10.0)

1 (3.3)

Elevated alkaline phosphatase

3 (10.0)

Hyperuricemia

3 (10.0)

Leukopenia

3 (10.0)

Sinus bradycardia

3 (10.0)

Odynophagia

2 (3.3)

Lymphopenia

2 (6.7)

Hypercholesterolemia

2 (6.7)

Diarrhea

2 (6.7)

Elevated Troponin T

2 (6.7)

Ventricular arrhythmia

2 (6.7)

Neutropenia

2 (6.7)

Gastrointestinal bleeding

1 (3.3)

Hypoalbuminemia

1 (3.3)

Oral mucositis

1 (3.3)

Nausea or vomiting

1 (3.3)

Rash and pruritis

1 (3.3)

1 (3.3)

Swollen gums

1 (3.3)

Hyponatremia

1 (3.3)

Hypophosphatemia

1 (3.3)

Hypoferremia

1 (3.3)

Thrombocytopenia

1 (3.3)

Anaemia

1 (3.3)

1 (3.3)

Sinus tachycardia

1 (3.3)